CNBC Stock Blog
- Why It’s Suddenly Exciting to Be a Yahoo Shareholder Again
- Goldman Investment Shines Light on Solar Power
- Facebook Options Soar on First Day
- Are You Ready for Facebook Options?
- Option Bulls Dig Into Ivanhoe Near Lows
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
ABOUT THE CNBC STOCK BLOG
ART CASHIN
RSS FEED
Option Bulls Bet Valeant’s Monster Run Will Continue
Writer, OptionMonster
Valeant Pharmaceuticals International has been an absolute monster stock for several months, and option traders are betting that the run will continue.
Bulls were going out in time yesterday, as more than 9,000 January 52.50 calls traded in a heavy buying pattern for $6 to $6.50, according to OptionMonster’s real-time systems. The open interest at the beginning of the session was just 13 contracts, so these were clearly new positions.
Valeant shares [VRX
Loading...
()
] closed yesterday up 1.13 percent to $48.45 as shares attempt to hold support at their 50-day moving average. The stock is up more than 50 percent since hitting a 52-week low of $32.05 on Oct. 4.
Earnings come out on Feb. 27 before the bell. For the calls
bought yesterday to turn a profit, the stock would need gain roughly 21 percent by expiration in 11 months.
Overall option volume in the name was more than four times its daily average. Calls at all strikes outnumbered puts
by 32 to 1, a reflection of yesterday’s bullish sentiment.
—Russell has no positions in VRX.
Additional News: Mylan Buys Two Dermatology Drugs From Valeant
Additional Views: Drug Stocks Do Well in ‘Gloom and Doom’ Market: Analyst
___________________________
Options Trading School:
___________________________
David Russell is a reporter and writer for OptionMonster.
___________________________












